Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02110381 · ClinicalTrials.gov registry record · NA

Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial

A NA study, sponsored by University of Michigan.

Terminated
Registry status
NA
Development phase
32
Enrollment target

NCT02110381 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02110381, a NA study, was terminated before completion, sponsored by University of Michigan.

TERMINATED
Registry status
NA
Development phase
32 participants
Enrollment target

Study Summary

An estimated 76 million adults in the United States over the age of 20 have hypertension (HTN); which translates into 1 out of 3 adults. Globally the prevalence of HTN is over 25% for adults, and accounts for approximately 13.5% of all deaths. Given the aging of the population together with increases in obesity and sedentary behavior, it is not surprising that HTN is projected to increase significantly over the next several decades; with over 1.5 billion adults having HTN by the year 2025. Thus the public health implications to preventing and/or reducing elevations in blood pressure are substantial. This study compares the efficacy of two different non-pharmacologic interventions (device guided breathing and isometric hand grip exercises) used alone and in combination for lowering blood pressure. This pilot study will include 30 adults with stage 1 hypertension. The primary outcome is the change in blood pressure from baseline to 8 weeks. Secondary outcomes include change in blood pressure from 8 weeks to 16 weeks and acceptability of the interventions by participants. The knowledge gained from this study can provide information on non-pharmacologic methods that may be useful in decreasing blood pressure. Such knowledge may be especially useful for patients for whom access to medications and health care is limited and among patients unwilling to take or intolerant to pharmacologic therapies.

Interventions

  • DEVICE Device guided breathing RESPeRATE
  • DEVICE Isometric hand grip Zona Plus

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2014-09
Est. Completion 2015-08
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT02110381

The ClinicalTrials.gov registry entry for NCT02110381 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Device guided breathing RESPeRATE is the first listed.

NCT02110381 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02110381 about?

NCT02110381 is a clinical study titled "Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial". An estimated 76 million adults in the United States over the age of 20 have hypertension (HTN); which translates into 1 out of 3 adults. Globally the prevalence of HTN is over 25% for adults, and accounts for approximately 13.5% of all deaths. Given the aging of the population together with increase...

What is the current status of trial NCT02110381?

This trial is currently terminated. It is a NA study. The enrollment target is 32 participants. The study started on 2014-09. Estimated completion is 2015-08.

What interventions are being tested in trial NCT02110381?

The interventions under investigation include: Device guided breathing RESPeRATE (DEVICE), Isometric hand grip Zona Plus (DEVICE).

Who is sponsoring clinical trial NCT02110381?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.